

CITATION REPORT

List of articles citing

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

DOI: 10.1016/j.coi.2011.12.009

Current Opinion in Immunology, 2012, 24, 207-12.

Source: <https://exaly.com/paper-pdf/53655644/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1102	Drug targets and predictive biomarkers in the management of metastatic melanoma. 2012 , 5, 139-48		3
1101	Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. 2012 , 2012, 818214		20
1100	Programmed death ligand 2 in cancer-induced immune suppression. 2012 , 2012, 656340		231
1099	Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities. 2012 , 3, 103		5
1098	PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint. 2012 , 1, 735-738		58
1097	B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim. 2012 , 1, 1061-1073		33
1096	Targeting PD-1/PD-L1 interactions for cancer immunotherapy. 2012 , 1, 1223-1225		248
1095	Role of the PD-1 pathway in the immune response. 2012 , 12, 2575-87		276
1094	Interleukin-27: balancing protective and pathological immunity. 2012 , 37, 960-9		187
1093	Recent developments on immunotherapy for brain cancer. 2012 , 17, 181-202		50
1092	Liberating tumor immunity. <i>Current Opinion in Immunology</i> , 2012 , 24, 204-6	7.8	1
1091	Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. 2012 , 10, 169		114
1090	Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. 2012 , 10, 108		10
1089	Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. 2012 , 366, 2443-54		8684
1088	New insights into chronic inflammation-induced immunosuppression. 2012 , 22, 307-18		145
1087	Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases. 2013 , 11, 4		35
1086	Metastatic melanoma to the brain: surgery and radiation is still the standard of care. 2013 , 14, 264-79		15

1085	Immunosuppressive mechanisms of regulatory dendritic cells in cancer. 2013 , 6, 159-67	60
1084	Oncology meets immunology: the cancer-immunity cycle. 2013 , 39, 1-10	3130
1083	Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. 2013 , 62, 629-37	40
1082	Tumor-associated macrophages: functional diversity, clinical significance, and open questions. 2013 , 35, 585-600	353
1081	Individualising treatment choices in a crowded treatment algorithm. 2013 , 11, 160-8	2
1080	Immune Stimulatory Features of Classical Chemotherapy. 2013 , 395-414	2
1079	Radiation as an immune modulator. 2013 , 23, 273-80	108
1078	Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. 2013 , 31, 4199-206	384
1077	Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. 2013 , 190, 4899-909	144
1076	Harnessing the immune system for the treatment of non-small-cell lung cancer. 2013 , 31, 1021-8	116
1075	Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity. 2013 , 191, 4121-9	70
1074	Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls. 2013 , 26 Suppl 1, S71-87	86
1073	Antibody therapeutics in cancer. 2013 , 341, 1192-8	412
1072	CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. 2013 , 19, 5300-9	485
1071	Oncolytic viruses as therapeutic cancer vaccines. 2013 , 12, 103	206
1070	Checkpoint modulation in melanoma: an update on ipilimumab and future directions. 2013 , 15, 500-8	17
1069	Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma. 2013 , 5, 607-19	3
1068	Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. 2013 , 49, 3229-41	35

1067	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. 2013 , 10, 588-98	145
1066	Immune Escape. 2013 , 149-164	1
1065	Current and future directions for Phase II trials in high-grade glioma. 2013 , 13, 369-87	4
1064	Enhanced expression of LAG-3 on lymphocyte subpopulations from persistently lymphocytotic cattle infected with bovine leukemia virus. 2013 , 36, 63-9	17
1063	Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. 2013 , 19, 462-8	407
1062	The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. 2013 , 19, 598-609	330
1061	Novel immunotherapeutic strategies in development for renal cell carcinoma. 2013 , 63, 881-9	31
1060	Human decidual macrophages suppress IFN- γ production by T cells through costimulatory B7-H1:PD-1 signaling in early pregnancy. 2013 , 100, 109-17	37
1059	Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response. 2013 , 21, 688-95	44
1058	Endocrine side effects induced by immune checkpoint inhibitors. 2013 , 98, 1361-75	299
1057	Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. 2013 , 13, 847-61	96
1056	Coinhibitory molecules in cancer biology and therapy. 2013 , 24, 147-61	24
1055	The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. 2013 , 139, 667-76	236
1054	Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future?. 2013 , 40, 347-60	13
1053	Immunomodulatory therapy for melanoma: ipilimumab and beyond. 2013 , 31, 191-9	45
1052	Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. 2013 , 62, 1369-80	23
1051	Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. 2013 , 12, 285-95	49
1050	Lungenkarzinom. 2013 , 8, 20-27	

1049	Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. 2013 , 19, 6151-62	80
1048	[Lung cancer. Molecular pathology and personalized therapy]. 2013 , 54, 179-80, 182-7	1
1047	[Personalized therapy concepts for malignant melanoma]. 2013 , 54, 188-93	3
1046	Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. 2013 , 19, 997-1008	144
1045	Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. 2013 , 31, 4311-8	447
1044	11th International Congress on Targeted Anticancer Therapies. 2013 , 3, 811-815	
1043	An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. 2013 , 12, 597-615	49
1042	Counteracting immunosuppressive cofactor B7-H1 may enhance the effects of chemotherapy in cancer patients. 2013 , 5, 557-9	2
1041	Immunotherapy treatments for small-cell lung cancer: past, present and future. 2013 , 2, 517-525	1
1040	CD4 T cell responses in latent and chronic viral infections. 2013 , 4, 105	17
1039	Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics. 2013 , 19, 348-52	16
1038	A new age for vaccine therapy in renal cell carcinoma. 2013 , 19, 365-70	15
1037	Strength of PD-1 signaling differentially affects T-cell effector functions. 2013 , 110, E2480-9	192
1036	Recent developments in chemotherapy for meningiomas: a review. 2013 , 35, E18	57
1035	HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. 2013 , 73, 1764-76	62
1034	What lies within: novel strategies in immunotherapy for non-small cell lung cancer. 2013 , 18, 1203-13	30
1033	Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. 2013 , 210, 2435-66	197
1032	Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. 2013 , 1, 158-62	94

1031	New combinations and immunotherapies for melanoma: latest evidence and clinical utility. 2013 , 5, 278-85	21
1030	Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies. 2013 , 4, 221	31
1029	Influence of tumors on protective anti-tumor immunity and the effects of irradiation. 2013 , 3, 14	7
1028	Combination of adoptive cell transfer, anti-PD-L1 and anti-LAG-3 antibodies for the treatment of recurrent tumors. 2013 , 2, e25050	4
1027	Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than "Exhaustion" of Human CD8 T Cells. 2013 , 4, 455	168
1026	PD-1 as a potential target in cancer therapy. 2013 , 2, 662-73	306
1025	Structure and interactions of the human programmed cell death 1 receptor. 2013 , 288, 11771-85	185
1024	Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. 2013 , 73, 3877-87	140
1023	Histone H2AX suppresses translocations in lymphomas of E μ -Myc transgenic mice that contain a germline amplicon of tumor-promoting genes. 2013 , 12, 2867-75	6
1022	Vaccine therapy for pancreatic cancer. 2013 , 2, e26662	40
1021	The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4 T cells. 2013 , 2, e23991	42
1020	gene expression in Japanese lung cancer patients. 2013 , 1, 93-96	10
1019	HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. 2013 , 122, 1448-54	18
1018	Current Advances in Therapy for Metastatic Melanoma. 2013 , 9, 8-23	
1017	Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed-Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist. 2013 , 37, 816-26	86
1016	Update on the challenges and recent advances in cancer immunotherapy. 2013 , 2, 39-49	7
1015	Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study. 2013 , 8, e61253	43
1014	Interferon- γ triggers hepatic stellate cell-mediated immune regulation through MEK/ERK signaling pathway. 2013 , 2013, 389807	16

1013	Combination Therapies to Improve Delivery of Protective T Cells into the Melanoma Microenvironment. 2013,	
1012	Avoidance of Cancer Cell Destruction by the Immune System. 2014, 434-443	
1011	Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via a proteasome-mediated degradation mechanism. 2014, 9, e99211	19
1010	Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma. 2014, 9, e106742	69
1009	Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy. 2014, 3, 151-65	9
1008	Precision cancer medicine: the future is now, only better. 2014, 61-9	30
1007	Out of the bitter came forth sweet: Activating CD28-dependent co-stimulation via PD-1 ligands. 2014, 3, e27399	15
1006	Emerging molecular targets in the treatment of nasopharyngeal carcinoma. 2014, 189-210	
1005	PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer. 2014, 105, 1229-35	54
1004	Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. 2014, 10, 3354-68	53
1003	Vaccines versus immunotherapy: overview of approaches in deciding between options. 2014, 10, 3369-74	9
1002	Potential roles of self-reactive T cells in autoimmunity: lessons from cancer immunology. 2014, 60, 156-64	2
1001	Is immune checkpoint modulation a potential therapeutic option in triple negative breast cancer?. 2014, 16, 457	2
1000	Lungenkarzinom. 2014, 17, 14-21	
999	Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. 2014, 74, 4042-52	94
998	Targeting COX-2 abrogates mammary tumorigenesis: Breaking cancer-associated suppression of immunosurveillance. 2014, 3, e29287	8
997	A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma. 2014, 6, 261-8	3
996	Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. 2014, 106,	122

995	Modulation of bone morphogenic protein signaling in T-cells for cancer immunotherapy. 2014 , 11, 319-27	13
994	The adaptation model of immunity. 2014 , 6, 59-70	8
993	Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. 2014 , 29, 153-61	60
992	Suppressive expression of CD274 increases tumorigenesis and cancer stem cell phenotypes in cholangiocarcinoma. 2014 , 105, 667-74	34
991	Evolving role of tumor antigens for future melanoma therapies. 2014 , 10, 1457-68	11
990	Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection. 2014 , 211, 515-27	101
989	B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction. 2014 , 20, 281-9	52
988	Vaccination therapy for non-small-cell lung cancer. 2014 , 26, 165-70	31
987	The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. 2014 , 26, 204-14	57
986	Dendritic cell cancer vaccines: from the bench to the bedside. 2014 , 5, e0024	9
985	Adjuvant therapy for renal cell carcinoma: past, present, and future. 2014 , 19, 851-9	47
984	Novel dendritic cell-based vaccination in late stage melanoma. 2014 , 10, 3132-8	10
983	Nasopharyngeal Carcinoma: Management Strategies. 2014 ,	1
982	Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. 2014 , 20, 1223-34	71
981	gene promoter polymorphisms correlate with a poor prognosis in non-small cell lung cancer. 2014 , 2, 1035-1042	18
980	Overcoming immunosuppression to enhance a p53MVA vaccine. 2014 , 3, e958949	8
979	Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues. 2014 , 5, 127	113
978	Cutaneous melanoma. 2014 , 383, 816-27	379

977	Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations. 2014 , 65, 33-41	35
976	Personalized Health Care (PHC) in Cancer. 2014 , 23-49	
975	Long-lasting complete response of metastatic melanoma to ipilimumab with analysis of the resident immune cells. 2014 , 31, 813	5
974	STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells. 2014 , 192, 4876-86	90
973	Targeting tumour-supportive cellular machineries in anticancer drug development. 2014 , 13, 179-96	169
972	The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. 2014 , 54, 289-96	548
971	T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. 2014 , 4, 522-6	246
970	Identification of B7-H1 as a novel mediator of the innate immune/proinflammatory response as well as a possible myeloid cell prognostic biomarker in sepsis. 2014 , 192, 1091-9	41
969	"In vitro" 3D models of tumor-immune system interaction. 2014 , 79-80, 145-54	63
968	Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. 2014 , 6, 459-75	76
967	Influence of PD-L1 cross-linking on cell death in PD-L1-expressing cell lines and bovine lymphocytes. 2014 , 142, 551-61	34
966	Treatment of HER2-positive breast cancer. 2014 , 23, 128-136	134
965	Biomarkers of renal cell carcinoma. 2014 , 32, 243-51	34
964	Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. 2014 , 11, 24-37	311
963	Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. 2014 , 123, 15-25	68
962	Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. 2014 , 92, 195-203	79
961	CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. 2014 , 22, 1949-59	212
960	Emerging immunotherapy strategies in breast cancer. 2014 , 6, 195-209	22

959	p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses. 2014 , 20, 4459-70	17
958	Gamma-retroviral vector design for the co-expression of artificial microRNAs and therapeutic proteins. 2014 , 24, 356-63	1
957	Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. 2014 , 211, 1905-18	151
956	Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy. 2014 , 63, 977-83	21
955	Stromal fibroblasts and the immune microenvironment: partners in mammary gland biology and pathology?. 2014 , 19, 169-82	25
954	PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. 2014 , 63, 395-406	111
953	Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. 2014 , 63, 545-57	76
952	The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. 2014 , 118, 557-99	32
951	High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer. 2014 , 14, 257	51
950	What have we learned from cancer immunotherapy in the last 3 years?. 2014 , 12, 141	25
949	Chronic thoracic spinal cord injury impairs CD8+ T-cell function by up-regulating programmed cell death-1 expression. 2014 , 11, 65	27
948	Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. 2014 , 32, 1020-30	1684
947	In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. 2014 , 20, 2773-82	337
946	Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer?. 2014 , 41, 126-32	40
945	The state of the art in non-small cell lung cancer immunotherapy. 2014 , 26, 26-35	7
944	The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. 2014 , 50, 627-32	161
943	Can calcium signaling be harnessed for cancer immunotherapy?. 2014 , 1843, 2334-40	6
942	The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. 2014 , 63, 925-38	46

941	Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy. 2014 , 2, 867-77	71
940	A review of novel therapies for melanoma. 2014 , 15, 323-37	44
939	Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. 2014 , 89, 504-19	63
938	Systemic and targeted therapies for early-stage lung cancer. 2014 , 21, 21-31	17
937	NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. 2014 , 12, 1629-49	12
936	Expression of immune checkpoint molecules in endometrial carcinoma. 2015 , 10, 1947-1952	26
935	[Molecular Concepts of Immunomodulation for the Treatment of Metastatic Renal Cell Carcinomas: Where are We Now?]. 2015 , 46, 473-80	
934	Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis. 2015 , 94, e515	79
933	Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. 2015 , 125, 1061-72	206
932	Immune Checkpoint Blockade in Hepatocellular Carcinoma. 2015 , 4, 201-7	36
931	Understanding Immune Checkpoint Inhibitors for Effective Patient Care. 2015 , 19, 709-17	15
930	Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. 2015 , 13, 374	11
929	B7-H1/PD-1 blockade therapy in urological malignancies: current status and future prospects. 2015 , 101, 549-54	5
928	Human IgG4: a structural perspective. 2015 , 268, 139-59	86
927	Clinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer: A Systematic Review and Meta-Analysis. 2015 , 94, e1911	21
926	Cytotoxic T-cell cytokines put cancer under arrest. 2015 , 3, 23-5	1
925	Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma. 2015 , 38, 285-91	27
924	Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside. 2015 , e291-7	4

923	The Evolution of Therapies in Non-Small Cell Lung Cancer. 2015 , 7, 1815-46	81
922	PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. 2015 , 10, e0136023	167
921	Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. 2015 , 2015, 851387	94
920	Clinical Development of Immune Checkpoint Inhibitors. 2015 , 2015, 605478	46
919	Human Tumor Antigens and Cancer Immunotherapy. 2015 , 2015, 948501	130
918	Principles of Cancer Immunobiology and Immunotherapy of Solid Tumors. 2015 ,	3
917	Recent Clinical Advances in the Treatment of Cutaneous Melanoma. 2015 , 2, 16-28	
916	Editorial: Personalized cancer treatment. 2014 , 7, 2-3	
915	Current therapeutic leads for the treatment of melanoma: targeted immunotherapy in the post-genomic era. 2014 , 7, 33-43	3
914	Myeloid-derived suppressor cells impair alveolar macrophages through PD-1 receptor ligation during Pneumocystis pneumonia. 2015 , 83, 572-82	28
913	Targeted Therapy for Metastatic Renal Cell Carcinoma: Introduction. 2015 , 1-14	
912	Programmed death-1 checkpoint blockade in acute myeloid leukemia. 2015 , 15, 1191-203	50
911	Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma. 2015 , 37, 1088-95	54
910	Immune modulation in advanced radiotherapies: Targeting out-of-field effects. 2015 , 368, 246-51	34
909	Immunostimulators and Immunomodulators in Cancer Treatment. 2015 , 411-431	
908	Immunotherapy for non-small-cell lung cancer: the past 10 years. 2015 , 11, 2681-2695	6
907	Development and Fit-for-Purpose Validation of a Soluble Human Programmed Death-1 Protein Assay. 2015 , 17, 976-87	8
906	PD-1 Restrains Radiotherapy-Induced Abscopal Effect. 2015 , 3, 610-9	251

905	Stereotactic radiosurgery and immunotherapy for metastatic spinal melanoma. 2015 , 38, E6	15
904	Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma. 2015 , 10, 925-35	7
903	Developments in T Cell Based Cancer Immunotherapies. 2015 ,	
902	The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance. 2015 , 12, 2072-85	26
901	Current and Emerging Perspectives on Immunotherapy for Melanoma. 2015 , 42 Suppl 3, S3-S11	17
900	Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3. 2015 , 290, 30018-29	64
899	[Rationale, visions and limits of Immuno-oncology: Checkpoint inhibition as a new pillar of tumor therapy]. 2015 , 38 Suppl 3, 2-5	1
898	[What opportunities does Immuno-oncology indicate for overarching long-term survival?]. 2015 , 38 Suppl 3, 6-11	1
897	Adoptive immunotherapy against sarcomas. 2015 , 15, 517-28	9
896	Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. 2015 , 42, 429-35	57
895	The lymph node microenvironment and its role in the progression of metastatic cancer. 2015 , 38, 98-105	103
894	PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. 2015 , 41, 114-21	126
893	Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. 2015 , 7, 12-21	20
892	Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer. 2015 , 15, 69-83	10
891	Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies. 2015 , 1, 64-78	118
890	Potential approaches for more successful dendritic cell-based immunotherapy. 2015 , 15, 569-82	24
889	Local-Regional Treatment of the Patient With Inflammatory Breast Cancer. 2015 , 7, 37-42	
888	Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells. 2015 , 3, 412-23	220

887	Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?. 2015 , 34, 129-44	9
886	Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression. 2015 , 4, e970462	24
885	Nivolumab and Olaparib. 2015 , 50, 356-66	2
884	Evolving Concepts: Immunity in Oncology from Targets to Treatments. 2015 , 2015, 847383	20
883	Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. 2015 , 4, e1008371	182
882	Feasibility of Penis-Preserving Surgery for Urethral Melanoma: Proposal for a Therapeutic Algorithm. 2015 , 13, e411-3	10
881	Inflammation and Lung Cancer: Molecular Pathology. 2015 , 69-93	
880	Inflammation and Lung Cancer. 2015 ,	0
879	Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein. 2015 , 4, e30	33
878	Surgical trauma induces postoperative T-cell dysfunction in lung cancer patients through the programmed death-1 pathway. 2015 , 64, 1383-92	24
877	Immune Targeting of Tumor Epithelial-Mesenchymal Transition via Brachyury-Based Vaccines. 2015 , 128, 69-93	12
876	Frequent expression of PD-L1 on circulating breast cancer cells. 2015 , 9, 1773-82	233
875	Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation. 2015 , 10, 910-23	390
874	OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. 2015 , 5, 34	161
873	Personalized immunotherapy (AGS-003) when combined with sunitinib for the treatment of metastatic renal cell carcinoma. 2015 , 15, 1241-8	15
872	Stereotactic body radiotherapy for oligometastatic disease. 2015 , 27, 290-7	22
871	Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. 2015 , 85, 703.e1-6	88
870	Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. 2015 , 88, 24-33	153

869	Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?. 2015 , 8, 16	67
868	Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. 2015 , 16, 64	329
867	Addressing the unmet need in lung cancer: The potential of immuno-oncology. 2015 , 41, 465-75	25
866	Regulatory T cells and potential immunotherapeutic targets in lung cancer. 2015 , 34, 277-90	21
865	Immunotherapeutic approaches to sarcoma. 2015 , 16, 26	37
864	Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives. 2015 , 76, 219-33	24
863	Overcoming T cell exhaustion in infection and cancer. 2015 , 36, 265-76	619
862	Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade. 2015 , 194, 3551-3555	37
861	Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma. 2015 , 16, e25-35	78
860	Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. 2015 , 21, 1127-38	45
859	Immune Therapy in GI Malignancies: A Review. 2015 , 33, 1745-53	29
858	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. 2015 , 33, 2004-12	859
857	Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. 2015 , 23, 1380-1390	67
856	Safety of pembrolizumab for the treatment of melanoma. 2015 , 14, 957-64	22
855	B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity. 2015 , 3, 184-95	28
854	Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. 2015 , 10, S1-63	102
853	PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. 2015 , 38, 1-11	270
852	Clinicoradiological spectrum of reversible splenic lesion syndrome (RESLES) in adults: a retrospective study of a rare entity. 2015 , 94, e512	39

851	Role of inflammatory infiltrates in triple negative breast cancer. 2015 , 68, 506-10	74
850	Immune evasion in cancer: Mechanistic basis and therapeutic strategies. 2015 , 35 Suppl, S185-S198	738
849	Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. 2015 , 112, 1421-7	168
848	Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice. 2015 , 3, 631-40	46
847	Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. 2015 , 50, 770-80	9
846	TGF β s a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. 2015 , 75, 2232-42	331
845	The immunobiology of interleukin-27. 2015 , 33, 417-43	239
844	The progress of immunotherapy for glioblastoma. 2015 , 11, 2654-8	5
843	Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. 2015 , 3, 1344-55	197
842	An optimized peptide vaccine strategy capable of inducing multivalent CD8 T cell responses with potent antitumor effects. 2015 , 4, e1043504	21
841	Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade. 2015 , 3, 449-54	61
840	Programmed death-1 & its ligands: promising targets for cancer immunotherapy. 2015 , 7, 777-92	16
839	Why has active immunotherapy not worked in lung cancer?. 2015 , 26, 2213-20	32
838	Emerging therapeutic approaches in renal cell carcinoma. 2015 , 15, 1305-14	12
837	The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. 2015 , 4, e1042198	31
836	Targeting immune checkpoints: New opportunity for mesothelioma treatment?. 2015 , 41, 914-24	33
835	Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. 2015 , 1, 66-75	60
834	HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. 2015 , 3, 1375-85	246

833	Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. 2015 , 21, 5453-9	237
832	Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. 2015 , 18, 325-32	117
831	Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. 2015 , 4, e1016700	156
830	Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells. 2015 , 21, 1010-7	109
829	Immunology and Immunotherapy of Head and Neck Cancer. 2015 , 33, 3293-304	381
828	Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. 2015 , 162, 1242-56	365
827	T-bet and interleukin-27: possible TH1 immunomodulators of sarcoidosis. 2015 , 23, 283-90	4
826	Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma. 2015 , 2, 41-50	6
825	Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies. 2015 , 10, 395-404	13
824	Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. 2015 , 42, 562-72	28
823	Kidney cancer and 2014: is innovation really over?. 2015 , 11, 1437-49	1
822	Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non-Small-Cell Lung Cancer. 2015 , 16, 385-90	94
821	Designing a broad-spectrum integrative approach for cancer prevention and treatment. 2015 , 35 Suppl, S276-S304	179
820	Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. 2015 , 7, 365-77	90
819	Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. 2015 , 9, 2054-62	60
818	T cell exhaustion and Interleukin 2 downregulation. 2015 , 71, 339-47	36
817	Renal Cell Carcinoma. 2015 ,	
816	Combination of radiotherapy and immune checkpoint inhibitors. 2015 , 25, 28-33	107

815	The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. 2015 , 191, 377-90	140
814	Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy. 2015 , 29, 25-32	32
813	PD-1 and Foxp3 T cell reduction correlates with survival of HCC patients after sorafenib therapy. 2016 , 1,	45
812	Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. 2016 , 7, 56233-56240	43
811	Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?. 2016 , 10, 293	38
810	Effects of lung cancer cell-associated B7-H1 on T-cell proliferation in vitro and in vivo. 2016 , 49,	0
809	T cell Bim levels reflect responses to anti-PD-1 cancer therapy. 2016 , 1,	52
808	Immunotherapy in urothelial carcinoma: fade or future standard?. 2016 , 5, 662-667	2
807	Immune checkpoint therapy for pancreatic cancer. 2016 , 22, 9457-9476	60
806	Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects. 2016 , 2016, 3850839	25
805	Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data. 2016 , 2016, 9839685	15
804	Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. 2016 , 2016, 4683607	29
803	Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer. 2016 , 2016, 2138627	18
802	Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer. 2016 , 2016, 4757405	29
801	Non-small cell lung cancer: current treatment and future advances. 2016 , 5, 288-300	762
800	Regulation of Natural Killer Cell Function by STAT3. 2016 , 7, 128	48
799	Advances in Cancer Immunotherapy in Solid Tumors. 2016 , 8,	109
798	Fibroblast Cell-Based Therapy for Experimental Autoimmune Diabetes. 2016 , 11, e0146970	9

797	Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients. 2016 , 9, 4805-13	29
796	The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials. 2016 , 9, 1571-8	6
795	Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives. 2016 , 138, 2549-61	119
794	Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells. 2016 , 380, 424-433	51
793	Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. 2016 , 68, 1079-89	102
792	Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer. 2016 , 138, 16686-16695	292
791	Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. 2016 , 6, 20090	111
790	Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. 2016 , 1,	58
789	Circulating memory T follicular helper subsets, Tfh2 and Tfh17, participate in the pathogenesis of Guillain-Barré syndrome. 2016 , 6, 20963	27
788	Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies. 2016 ,	2
787	Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. 2016 , 58, 59-70	78
786	Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy. 2016 , 30, 263-73	19
785	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. 2016 , 11, 593-603	12
784	Targeting PD-L1 for non-small-cell lung cancer. 2016 , 8, 747-58	10
783	Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. 2016 , 8, 705-19	48
782	Phase I study to evaluate toxicity and feasibility of intratumoral injection of E ₁ gal glycolipids in patients with advanced melanoma. 2016 , 65, 897-907	8
781	Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma. 2016 , 4, 531-40	16
780	Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8+ T cells. 2016 , 35, 699-708	48

779	Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies. 2016 , 57, 1269-80	4
778	Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. 2016 , 29, 587-601	259
777	Chordoma: The Quest for Better Treatment Options. 2016 , 4, 35-51	23
776	Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. 2016 , 34, 2460-7	867
775	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. 2016 , 17, 717-726	716
774	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. 2016 , 13, 473-86	591
773	Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology. 2016 , 44, 1000-1009	37
772	Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. 2016 , 76, 6964-6974	200
771	Plasma Cell Dyscrasias. 2016 ,	1
770	Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma. 2016 , 169, 207-225	13
769	Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines. 2016 , 40, 151-162	16
768	The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. 2016 , 61, 152-8	40
767	Sensitivity of dendritic cells to NK-mediated lysis depends on the inflammatory environment and is modulated by CD54/CD226-driven interactions. 2016 , 100, 781-789	9
766	B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8 T cells. 2016 , 6, 36722	26
765	Clinical relevance of expression of B7-H1 and B7-H4 in ovarian cancer. 2016 , 11, 2815-2819	11
764	Emerging Systemic Therapies for the Management of Penile Cancer. 2016 , 43, 481-491	9
763	Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma. 2016 , 12, 1089-96	15
762	Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. 2016 , 8, 775-84	19

761	Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung. 2016 , 99, 117-9	70
760	MicroRNA expression profiling in Guillain-Barré syndrome. 2016 , 301, 12-15	7
759	Immunothérapie et cancer du sein. 2016 , 18, 551-558	2
758	Magneto-nanosensor platform for probing low-affinity protein-protein interactions and identification of a low-affinity PD-L1/PD-L2 interaction. 2016 , 7, 12220	23
757	BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma. 2016 , 8, 1351-1353	6
756	Interdependent IL-7 and IFN- γ signalling in T-cell controls tumour eradication by combined CTLA-4+PD-1 therapy. 2016 , 7, 12335	63
755	Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. 2016 , 7, 12499	484
754	Recent Trends in the Management of Hepatocellular Carcinoma with Special Emphasis on Treatment with Regorafenib and Immune Checkpoint Inhibitors. 2016 , 34, 714-730	7
753	The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma. 2016 , 38, 81-9	26
752	Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. 2016 , 21, 804-16	156
751	Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. 2016 , 13, 420-31	66
750	Immunopharmacology. 2016 ,	3
749	Checkpoint Inhibitors and Their Application in Breast Cancer. 2016 , 11, 108-15	33
748	A role for pre-mNK cells in tumor progression. 2016 , 4, 16	5
747	Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. 2016 , 69, 25-34	138
746	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. 2016 , 4, 3	146
745	New insights into the anti-PD-L1 and anti-PD-1 reagents in cancer therapy. 2016 , 14, 61-65	
744	A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. 2016 , 31, 248-56	11

743	Pembrolizumab for the treatment of non-small cell lung cancer. 2016 , 16, 397-406	52
742	Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. 2016 , 48, 177-87	141
741	PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. 2016 , 47, 52-63	214
740	A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice. 2016 , 5, e1147641	30
739	Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer. 2016 , 59, 65-78	24
738	Emerging Molecular Targets in the Treatment of Head and Neck Squamous Cell Carcinoma. 2016 , 163-209	
737	Immunotherapy for head and neck cancer: latest developments and clinical potential. 2016 , 8, 168-75	12
736	Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. 2016 , 5, e1085147	94
735	Microsatellite Instability as a Biomarker for PD-1 Blockade. 2016 , 22, 813-20	470
734	Targeting the tumour microenvironment in ovarian cancer. 2016 , 56, 131-143	69
733	Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. 2016 , 22, 3630-42	246
732	Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6. 2016 , 5, e1091555	26
731	Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in Mice. 2016 , 4, 441-51	21
730	Targeting Oral Cancer. 2016 ,	
729	MYC regulates the antitumor immune response through CD47 and PD-L1. 2016 , 352, 227-31	651
728	Regulation of PD-L1: a novel role of pro-survival signalling in cancer. 2016 , 27, 409-16	429
727	Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN γ That Induce PD-L1 Expression in Head and Neck Cancer. 2016 , 76, 1031-43	193
726	Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. <i>Current Opinion in Immunology</i> , 2016 , 39, 30-8	7.8 18

725	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. 2016 , 11, 345-51	48
724	Small cell lung cancer: Recruitment of macrophages by circulating tumor cells. 2016 , 5, e1093277	44
723	Immunotherapy and tumor microenvironment. 2016 , 370, 85-90	164
722	Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. 2016 , 18, 497-506	80
721	Cancer immunotherapy in veterinary medicine: Current options and new developments. 2016 , 207, 20-28	36
720	Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status. 2016 , 23, 694-702	108
719	Biology of Lung Cancer. 2016 , 912-926.e6	0
718	Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. 2017 , 13, 195-207	381
717	In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy. 2017 , 1,	278
716	Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro. 2017 , 6, 221-232	9
715	Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. 2017 , 33, 749-759	50
714	Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. 2017 , 8, 14572	191
713	Emerging role of checkpoint blockade therapy in lymphoma. 2017 , 8, 81-90	20
712	FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma. 2017 , 23, 5666-5670	63
711	Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma. 2017 , 18, 7	40
710	PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. 2017 , 7, 44173	50
709	New monoclonal antibodies on the horizon in multiple myeloma. 2017 , 8, 41-53	13
708	Hypoxia-inducing factor (HIF)-1 β -derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24 patients with renal cell carcinoma. 2017 , 44, 197-202	6

707	LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. 2017 , 12, 814-823	122
706	PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. 2017 , 23, 3711-3720	460
705	Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials. 2017 , 92 Suppl 1, 50-62	120
704	Targeting TGF- β Signaling for Therapeutic Gain. 2017 , 9,	98
703	IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model. 2017 , 486, 239-244	75
702	Dendritic cells infected by Ad-sh-SOCS1 enhance cytokine-induced killer (CIK) cell immunotherapeutic efficacy in cervical cancer models. 2017 , 19, 617-628	6
701	FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma. 2017 , 23, 5661-5665	50
700	Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity. 2017 , 17, 515-523	36
699	Immune checkpoints and their inhibition in cancer and infectious diseases. 2017 , 47, 765-779	260
698	PD-L1 expression in extrahepatic cholangiocarcinoma. 2017 , 71, 383-392	45
697	Childhood Acute Lymphoblastic Leukemia. 2017 ,	
696	Nanotechnology based therapeutic modality to boost anti-tumor immunity and collapse tumor defense. 2017 , 256, 26-45	27
695	Management of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma: A nursing perspective. 2017 , 29, 294-303	9
694	Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy. 2017 , 28, 1658-1666	17
693	Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. 2017 , 28, 1388-1398	54
692	Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis. 2017 , 96, e6369	113
691	Immunobiology and Immune Based Therapies of Melanoma. 2017 , 871-890	
690	Design and Applications of Nanoparticles in Biomedical Imaging. 2017 ,	9

689	Chloroquine (CQ) exerts anti-breast cancer through modulating microenvironment and inducing apoptosis. 2017 , 42, 100-107	19
688	Overcoming immunosuppression in bone metastases. 2017 , 117, 114-127	19
687	Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma. 2017 , 58, 1560-1566	52
686	Immunogenomics: using genomics to personalize cancer immunotherapy. 2017 , 471, 209-219	5
685	Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. 2017 , 102, 2770-2780	125
684	B7-H4 is a prognostic biomarker for poor survival in patients with pancreatic cancer. 2017 , 66, 79-85	18
683	The JAK/STAT3 axis: A comprehensive drug target for solid malignancies. 2017 , 45, 13-22	105
682	Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression. 2017 , 5, 560-570	7
681	Acquired IFN γ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. 2017 , 8, 15440	125
680	Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study. 2017 , 6, e1304337	12
679	Understanding the checkpoint blockade in lung cancer immunotherapy. 2017 , 22, 1266-1273	36
678	Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. 2017 , 19, 203-217	278
677	Optimizing Radiotherapy with Immunotherapeutic Approaches. 2017 , 995, 53-71	10
676	Pembrolizumab for the treatment of non-small cell lung cancer. 2017 , 17, 399-409	24
675	CD8 T-cell regulation by T regulatory cells and the programmed cell death protein 1 pathway. 2017 , 151, 146-153	8
674	Strategies for Increasing Pancreatic Tumor Immunogenicity. 2017 , 23, 1656-1669	92
673	An Anti-Programmed Death-1 Antibody (PD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional PD-1 Nanoparticle. 2017 , 14, 1494-1500	18
672	Cancer Immunotherapy: Whence and Whither. 2017 , 15, 635-650	24

671	Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. 2017 , 66, 877-890	93
670	Frequency and functional characterization of exhausted CD8 T cells in chronic lymphocytic leukemia. 2017 , 98, 622-631	33
669	Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies Inactivation Impairing Immunorecognition. 2017 , 23, 3203-3213	45
668	Immunotherapy. 2017 ,	4
667	Triggered Drug Release and Enhanced Drug Transport from Ultrasound-Responsive Nanoparticles. 2017 , 277-297	1
666	Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. 2017 , 123, 1259-1271	40
665	Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition. 2017 , 23, 3203-3213	45
664	Epithelial-mesenchymal plasticity in circulating tumor cells. 2017 , 95, 133-142	85
663	PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. 2017 , 162, 19-30	70
662	Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update. 2016 , 6, 1-12	42
661	Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. 2017 , 50, 41-48	49
660	B7-H3 promotes the proliferation, migration and invasiveness of cervical cancer cells and is an indicator of poor prognosis. 2017 , 38, 1043-1050	20
659	Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth. 2017 , 11, 10135-10146	60
658	Gene editing in T cell therapy. 2017 , 44, 415-422	13
657	Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. 2017 , 40, 334-340	15
656	Restoration of Natural Killer Cell Antimetastatic Activity by IL12 and Checkpoint Blockade. 2017 , 77, 7059-7071	52
655	Avelumab and other recent advances in Merkel cell carcinoma. 2017 , 13, 2771-2783	9
654	Improvement of cytotoxicity of autologous CIKs from patients with breast cancer to MCF-7 cells by suppressed PD-1 expression. 2017 , 20, 609-615	3

653	Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. 2017 , 32, 1-15	76
652	The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease. 2018 , 103, 565-575	35
651	Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). 2017 , 16, 1255-1271	72
650	Novel Immunologic Approaches to Melanoma Treatment. 2017 , 108, 708-720	
649	Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. 2017 , 6, e1338237	36
648	Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1. 2017 , 66, 1920-1933	85
647	Novel Immunologic Approaches to Melanoma Treatment. 2017 , 108, 708-720	6
646	Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models. 2017 , 7, 2476	26
645	Status quo: Immuntherapie in der Uroonkologie. 2017 , 38, 386-389	
644	Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma. 2017 , 7, 378-382	17
643	Checkpoint Blockade Plus Oncolytic Virus: A Hot Therapeutic Cancer Strategy. 2017 , 23, 983-985	7
642	The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis. 2017 , 7, 4231	48
641	Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. 2017 , 77, 839-850	145
640	Basis for molecular diagnostics and immunotherapy for esophageal cancer. 2017 , 17, 33-45	19
639	Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. 2017 , 80, 7-14	28
638	Immunotherapy Comes of Age in Lung Cancer. 2017 , 18, 13-22	49
637	Epitope-Specific Antitumor Immunity Suppresses Tumor Spread in Papillary Thyroid Cancer. 2017 , 102, 2154-2161	6
636	Combining Radiotherapy and Immunotherapy: Emerging Preclinical Observations of Lymphocyte Costimulatory and Inhibitory Receptor Modulation. 2017 , 151-169	

635	Increasing the Therapeutic Ratio of Radiotherapy. 2017 ,	1
634	Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: A meta-analysis of randomized clinical trials. 2017 , 96, e8931	17
633	Contribution of Adipose Tissue to Development of Cancer. 2017 , 8, 237-282	89
632	Immune Checkpoint Blockade in Breast Cancer Therapy. 2017 , 1026, 383-402	22
631	Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update. 2017 , 93 Suppl 1, 147-159	69
630	Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery. 2017 , 23, 4716-4725	6
629	Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage. 2018 , 52, 379-388	11
628	HDAC inhibition potentiates immunotherapy in triple negative breast cancer. 2017 , 8, 114156-114172	89
627	Immunotherapy in Gastrointestinal Cancers. 2017 , 2017, 4346576	45
626	Role of tumor microenvironment in tumorigenesis. 2017 , 8, 761-773	702
625	PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. 2017 , 8, 561	804
624	Changes in T Cell and Dendritic Cell Phenotype from Mid to Late Pregnancy Are Indicative of a Shift from Immune Tolerance to Immune Activation. 2017 , 8, 1138	41
623	Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients. 2017 , 18,	45
622	Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8 T Cell Responses to Chronic Viral Infections and Cancer. 2017 , 8, 1215	55
621	"Targeted" Chemotherapy for Esophageal Cancer. 2017 , 7, 63	14
620	Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting-Practice and Outcomes. 2017 , 7, 151	2
619	Circulating tumor cell interactions with macrophages: implications for biology and treatment. 2017 , 6, 418-430	28
618	The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma. 2017 , 9,	21

617	Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200. 2017 , 9, 601-609	15
616	Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. 2017 , 10, 3697-3708	4
615	Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. 2017 , 17, 618	25
614	Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. 2017 , 19, 91	59
613	Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report. 2017 , 3, 94	12
612	Aktuelle Immuntherapien des malignen Melanoms. 2017 , 20, 16-20	
611	Nivolumab for the Treatment of Classical Hodgkin Lymphoma. 2017 , 33, 237-244	78
610	Cancer Immunotherapy. 2017 , 32-65	1
609	The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies. 2017 , 5,	8
608	Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas. 2017 , 23, 3593-3602	17
607	PD-1 and its ligands are important immune checkpoints in cancer. 2017 , 8, 2171-2186	158
606	Yes-associated protein and immunosuppressive microenvironment in pancreatic cancer development: a new strategy to improve immunotherapy efficacy?. 2017 , 9, 1798-1801	
605	Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling. 2017 , 8, 98215-98232	18
604	Targeting Melanoma with Cancer-Killing Viruses. 2017 , 11, 28-47	8
603	Targeting the microenvironment in solid tumors. 2018 , 65, 22-32	189
602	PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma. 2018 , 67, 805-814	27
601	Hypoxia and acidosis: immune suppressors and therapeutic targets. 2018 , 154, 354-362	83
600	Sequentially Responsive Therapeutic Peptide Assembling Nanoparticles for Dual-Targeted Cancer Immunotherapy. 2018 , 18, 3250-3258	180

599	IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer. 2018 , 6, 645-657	19
598	DNA mismatch repair in cancer. 2018 , 189, 45-62	171
597	Emerging Systemic Therapies for Colorectal Cancer. 2018 , 31, 179-191	13
596	Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer. 2018 , 41, 18-27	14
595	Circulating histocompatibility antigen (HLA) gene products may help differentiate benign from malignant indeterminate pulmonary lesions. 2018 , 79, 558-563	2
594	Dynamics of Lymphocyte Reconstitution After Hematopoietic Transplantation During Chronic Lymphocytic Choriomeningitis Virus Infection. 2018 , 34, 430-438	2
593	Sustained release of anti-PD-1 peptide for perdurable immunotherapy together with photothermal ablation against primary and distant tumors. 2018 , 278, 87-99	71
592	MicroRNA-374b inhibits liver cancer progression via down regulating programmed cell death-1 expression on cytokine-induced killer cells. 2018 , 15, 4797-4804	20
591	Rescue of iCIKs transfer from PD-1/PD-L1 immune inhibition in patients with resectable tongue squamous cell carcinoma (TSCC). 2018 , 59, 127-133	5
590	Harnessing macrophages in thermal and non-thermal ablative therapies for urologic cancers □ Potential for immunotherapy. 2018 , 1, 5-11	1
589	Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model. 2018 , 105, 146-154	15
588	Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. 2018 , 16, 176-183	10
587	Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma. 2018 , 28, 105-113	16
586	Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-□ 2018 , 10,	239
585	Translation in Immunology. 2018 , 1-11	
584	Individualizing the Approach to the Older Woman with Triple-Negative Breast Cancer. 2018 , 159-177	
583	Triple-Negative Breast Cancer. 2018 ,	
582	High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. 2018 , 24, 144-153	374

581	First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy. 2018 , 34, 825-831	9
580	Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma. 2018 , 105, 493-501	23
579	AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma. 2018 , 40, 676-686	10
578	IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. 2018 , 67, 320-332	255
577	Fading With Time of PD-L1 Immunoreactivity in Non-Small Cells Lung Cancer Tissues: A Methodological Study. 2018 , 26, 489-494	31
576	PD-1 and cancer: molecular mechanisms and polymorphisms. 2018 , 70, 73-86	62
575	In Vitro Modeling of Tumor-Immune System Interaction. 2018 , 4, 314-323	15
574	Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. 2018 , 26, 83-93	88
573	Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. 2018 , 32, 960-970	76
572	Immunotherapy as an Option for Cancer Treatment. 2018 , 66, 89-96	13
571	A review of immune therapy in cancer and a question: can thermal therapy increase tumor response?. 2018 , 34, 840-852	16
570	Immunotherapy and Lung Cancer. 2018 , 501-511.e3	2
569	PD-L1 inhibitors in the pipeline: Promise and progress. 2017 , 7, e1365209	27
568	Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. 2018 , 23, 71-83	34
567	The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. 2018 , 178, 173-180	74
566	Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells. 2018 , 72, 135-143	10
565	Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy. 2018 , 79, e12795	52
564	Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening. 2018 , 67, 471-481	4

563	PD-L1. 2018 , 71, 189-194	129
562	Anti-PD-L1/TGFB2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. 2018 , 36, 93.e1-93.e11	23
561	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. 2018 , 7, e1405206	27
560	Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies. 2018 , 14, 32-39	63
559	Aktuelle Immuntherapien des malignen Melanoms. 2018 , 21, 44-51	
558	Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC). 2018 , 9, 17554-17563	16
557	Immunotherapy in previously treated non-small cell lung cancer (NSCLC). 2018 , 10, S422-S432	6
556	"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer": is there a substantial difference or not?. 2018 , 10, S4065-S4068	13
555	Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer. 2018 , 24, 3583-3616	74
554	The Immune Regulatory Role of Cytokine-Induced Killer Cells Treatment on Non-Small Cell Lung Cancer Patients. 2018 ,	
553	Tumor Immunology: Uncovering Relationship Between Cancer and Immune System. 2018 , 10,	
552	Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer. 2018 , 9, 258-277	51
551	Perspective: cancer vaccines in the era of immune checkpoint blockade. 2018 , 29, 703-713	11
550	Interferon- β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells. 2018 , 507, 330-336	31
549	Therapy Implications of DNA Mismatch Repair Deficiency, Microsatellite Instability, and Tumor Mutation Burden. 2018 , 1, 193-208	3
548	PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells. 2019 , 14, 17-32	44
547	Strategies of Combination Drug Delivery for Immune Checkpoint Blockades. 2019 , 8, e1801099	17
546	Development of PARP and Immune-Checkpoint Inhibitor Combinations. 2018 , 78, 6717-6725	106

545	Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. 2018 , 10, 93	77
544	Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort. 2018 , 14, 1691-1700	6
543	Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer. 2018 , 38, 5569-5580	32
542	The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge. 2018 , 21, 233-243	36
541	The comprehensive molecular landscape of the immunologic co-stimulator B7 and TNFR ligand receptor families in colorectal cancer: immunotherapeutic implications with microsatellite instability. 2018 , 7, e1488566	8
540	Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. 2018 , 6, 111	79
539	[Tumour assessment criteria for immune checkpoint inhibitors]. 2018 , 35, 828-845	2
538	A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. 2018 , 119, 1200-1207	59
537	A Novel 3D in Vitro Tumor Model Based on Silk Fibroin/Chitosan Scaffolds To Mimic the Tumor Microenvironment. 2018 , 10, 36641-36651	36
536	Combinations of Bevacizumab With Cancer Immunotherapy. 2018 , 24, 193-204	89
535	Translational Biomarkers: Application in the Clinical Development of Combination Therapies. 2018 , 223-248	
534	Prognostic significance of programmed death ligand-1 immunohistochemical expression in esophageal cancer: A meta-analysis of the literature. 2018 , 97, e11614	12
533	An overview of cancer immunotherapeutic strategies. 2018 , 10, 999-1010	13
532	Variability of PD-L1 expression in mastocytosis. 2018 , 2, 189-199	5
531	Head and Neck Tumors. 2018 , 1-136	1
530	The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients. 2018 , 22, 467-476	18
529	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. 2018 , 56, 460-472	13
528	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. 2018 , 430, 2014-2029	30

527	Aktuelle Immuntherapien des malignen Melanoms. 2018 , 34, 32-38	
526	Combination Immunotherapy Approaches for Pancreatic Cancer Treatment. 2018 , 2018, 6240467	9
525	Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. 2018 , 7, e1466018	32
524	The Single-Cell Phenotypic Identity of Human CD8 and CD4 T Cells. 2018 , 341, 63-124	33
523	B7-H1 Expression Is Required for Human Endometrial Regenerative Cells in the Prevention of Transplant Vasculopathy in Mice. 2018 , 2018, 2405698	7
522	Roles of MALAT1 in development and migration of triple negative and Her-2 positive breast cancer. 2018 , 9, 2255-2267	24
521	Tumor Necrosis Factor and Regulatory T Cells in Oncoimmunology. 2018 , 9, 444	66
520	Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. 2018 , 9, 727	25
519	Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma. 2018 , 9, 1370	22
518	The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas. 2018 , 11, 82	37
517	Immunotherapy Plus Cryotherapy: Potential Augmented Abscopal Effect for Advanced Cancers. 2018 , 8, 85	43
516	Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy. 2018 , 10,	108
515	Differential Expression of Immune Inhibitory Checkpoint Signatures on Antiviral and Inflammatory T Cell Populations in Chronic Hepatitis B. 2018 , 38, 273-282	10
514	Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses. 2018 , 26, 2315-2325	25
513	Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. 2018 , 66, 104-113	57
512	Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC. 2018 , 18, 123	11
511	Immunotherapy in Breast Cancer: the New Frontier. 2018 , 10, 35-40	16
510	Delivery of interleukin-22 binding protein (IL-22BP) gene by cationic micelle for colon cancer gene therapy.. 2018 , 8, 16537-16548	4

509	Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians. 2018 , 55, 489-502	45
508	New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. 2018 , 1, 21-28	8
507	Immune Checkpoint Ligand PD-L1 Is Upregulated in Pulmonary Lymphangiomyomatosis. 2018 , 59, 723-732	19
506	Ultra-small Albumin Templated Gd/Ru Composite Nanodots for In Vivo Dual modal MR/Thermal Imaging Guided Photothermal Therapy. 2018 , 7, e1800322	20
505	Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer. 2018 , 57, 1269-1272	22
504	Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy. 2018 , 9, 1774	66
503	Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy. 2018 , 15, 4426-4433	23
502	IDO-expressing Fibroblasts Suppress the Development of Imiquimod-induced Psoriasis-like Dermatitis. 2018 , 27, 557-570	3
501	Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. 2019 , 52, 144-160	9
500	TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2. 2019 , 10, 1644	14
499	Sex differences in the therapeutic effects of anti-PDL2 neutralizing antibody on stroke. 2019 , 34, 1705-1712	4
498	BRAF-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. 2019 , 38, 6752-6766	30
497	Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view. 2019 , 233, 116713	25
496	Avelumab in gastric cancer. 2019 , 11, 759-768	8
495	Signet Ring Cell Carcinoma of the Lung: A Diagnostic Pitfall in Pregnancy. 2019 , 2019, 9461579	2
494	Application of CAR T cells for the treatment of solid tumors. 2019 , 164, 293-327	7
493	Small-Molecule Poly(ADP-ribose) Polymerase and PD-L1 Inhibitor Conjugates as Dual-Action Anticancer Agents. 2019 , 4, 12584-12597	7
492	The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era. 2019 , 21, 76	15

491	Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors. 2019 , 20,	23
490	Development of Tc-conjugated JS001 antibody for in vivo mapping of PD-1 distribution in murine. 2019 , 29, 2178-2181	5
489	TAZ teases T cells with PD-L1. 2019 , 8, 322-326	
488	MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells. 2019 , 8, 7044-7054	18
487	Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. 2019 , 145, 3021-3036	11
486	Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma. 2019 , 8, 6585-6594	21
485	Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. 2019 , 12, 111	45
484	The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors. 2019 , 19, 993-999	6
483	Potential prognostic value of PD-L1 and FOXP3 as predictors of relapse in breast cancer. 2019 , 9, 38	
482	Improved Anti-Tumour Adaptive Immunity Can Overcome the Melanoma Immunosuppressive Tumour Microenvironment. 2019 , 11,	4
481	PLGA Nanoparticles Codelivering siRNAs against Programmed Cell Death Protein-1 and Its Ligand Gene for Suppression of Colon Tumor Growth. 2019 , 16, 4940-4953	19
480	A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients. 2019 , 10, 1832	30
479	GAPDH Overexpression in the T Cell Lineage Promotes Angioimmunoblastic T Cell Lymphoma through an NF- κ B-Dependent Mechanism. 2019 , 36, 268-287.e10	15
478	Ultrathin Metal-Organic-Layer Mediated Radiotherapy-Radiodynamic Therapy. 2019 , 1, 1331-1353	55
477	Future therapeutic strategies for metastatic prostate cancer. 2019 , 9, 117-130	4
476	The promising role of monoclonal antibodies for gastric cancer treatment. 2019 , 11, 347-364	7
475	PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population. 2019 , 14, 6	17
474	Head and Neck Tumors. 2019 , 627-762	

473	Immune therapy of melanoma: Overview of therapeutic vaccines. 2019 , 234, 14612	18
472	Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer. 2019 , 17, 91-97	25
471	CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. 2019 , 37, 457-495	528
470	Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy. 2019 , 566, 731-744	29
469	CD8 PD-1 T-cells and PD-L1 circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?. 2019 , 11, 1758835919853193	5
468	Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. 2019 , 460, 42-53	37
467	Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma. 2019 , 129, 90-100	32
466	The 100 top-cited studies in cancer immunotherapy. 2019 , 47, 2282-2292	16
465	The Epitope-Specific Anti-human CD4 Antibody MAX.16H5 and Its Role in Immune Tolerance. 2019 , 10, 1035	4
464	Epidermolysis bullosa: Advances in research and treatment. 2019 , 28, 1176-1189	25
463	State of art of advanced triple negative breast cancer. 2019 , 25, 967-970	13
462	Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. 2019 , 5, 1132-1140	135
461	Advances in Therapies and Imaging for Systemic Vasculitis. 2019 , 39, 1520-1541	14
460	Pembrolizumab for the Treatment of Hepatocellular Carcinoma. 2019 , 8, 143-154	14
459	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. 2019 , 39, 147-164	248
458	Computational analysis of hot spots and binding mechanism in the PD-1/PD-L1 interaction.. 2019 , 9, 14944-14956	56
457	Tumour microenvironment responsive nanoconstructs for cancer theranostic. 2019 , 26, 16-56	73
456	Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab. 2019 , 18, 1536012119829986	33

455	Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma. 2019 , 145, 763-774	14
454	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. 2019 , 143, 63-144	26
453	LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195. 2019 , 231, 116335	72
452	Tissue-resident cytotoxic innate lymphoid cells in tumor immunosurveillance. 2019 , 41, 101269	8
451	Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer. 2019 , 12,	8
450	Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors. 2019 , 9, 52	23
449	Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling. 2019 , 131, 58-61	11
448	A Dual-Bioresponsive Drug-Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade. 2019 , 31, e1806957	95
447	Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells. 2019 , 9, 4532	33
446	YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. 2019 , 43, 10-28	51
445	Autophagy inhibition enhances PD-L1 expression in gastric cancer. 2019 , 38, 140	54
444	Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. 2019 , 18, 60	169
443	PD-L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling. 2019 , 41, 2833-2843	9
442	Tolerizing CTL by Sustained Hepatic PD-L1 Expression Provides a New Therapy Approach in Mouse Sepsis. 2019 , 9, 2003-2016	7
441	Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with anti-programmed cell death 1 (anti-PD-1) therapy. 2019 , 11, 577-584	13
440	New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment. 2019 , 38, 91	38
439	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. 2019 , 8, e1801320	25
438	Acute Traumatic Brain Injury Induces CD4+ and CD8+ T Cell Functional Impairment by Upregulating the Expression of PD-1 via the Activated Sympathetic Nervous System. 2019 , 26, 43-57	13

437	PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer. 2019 , 8, e1544442	32
436	Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?. 2019 , 49, 265-271	3
435	Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies. 2019 , 24, 549-554	55
434	Elevated circulating T cell subsets and cytokines expression in patients with rheumatoid arthritis. 2019 , 38, 1831-1839	16
433	PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy. 2019 , 234, 16824-16837	152
432	Novel targets to develop new antibacterial agents and novel alternatives to antibacterial agents. 2019 , 11, 100052	41
431	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. 2019 , 24, 1259-1269	67
430	T-Regulatory Cells In Tumor Progression And Therapy. 2019 , 11, 10731-10747	31
429	Engineering Nanoparticles to Reprogram the Tumor Immune Microenvironment for Improved Cancer Immunotherapy. 2019 , 9, 7981-8000	71
428	Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies. 2019 , 8, 413-426	16
427	Interactions between hydatid cyst and regulated cell death may provide new therapeutic opportunities. 2019 , 26, 70	2
426	Posttransplant maintenance therapy for acute leukemias. 2019 , 26, 96-111	2
425	33 Targeted Therapy for the Treatment of Advanced Squamous Cell Carcinoma of the Larynx. 2019 ,	
424	The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers. 2019 , 46, 3-10	8
423	PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. 2019 , 234, 1313-1325	127
422	MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma. 2019 , 27, 67-74	36
421	Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. 2019 , 14, 494-502	64
420	Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. 2019 , 18, 197-218	981

419	Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy. 2019 , 293, 104-112	35
418	A new immune-nanoplatform for promoting adaptive antitumor immune response. 2019 , 17, 13-25	9
417	Alterations of the Immunologic Co-Stimulator B7 and TNFR Families Correlate with Hepatocellular Carcinoma Prognosis and Metastasis by Inactivating STAT3. 2019 , 20,	10
416	Tumor-Targeted Chemoimmunotherapy with Immune-Checkpoint Blockade for Enhanced Anti-Melanoma Efficacy. 2019 , 21, 18	5
415	Expression of programmed death-1 (PD-1) and its ligand PD-L1 is upregulated in endometriosis and promoted by 17beta-estradiol. 2019 , 35, 251-256	17
414	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. 2019 , 79, 1214-1225	117
413	Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF- κ B Activation and PD-L1 Expression. 2019 , 73, 22-35.e6	108
412	PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma. 2019 , 28, 546-554	31
411	Dysregulation of key microRNAs in pancreatic cancer development. 2019 , 109, 1008-1015	28
410	Combination of novel systemic agents and radiotherapy for solid tumors - part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy. 2019 , 134, 87-103	4
409	RNA In Situ Hybridization for Epstein-Barr Virus and Cytomegalovirus: Comparison With In Situ Hybridization and Immunohistochemistry. 2019 , 27, 155-159	11
408	Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?. 2019 , 343, 103753	108
407	Targeting metabolic reprogramming in metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT). 2020 , 98, 192-201	20
406	Therapeutic Antibodies and Immunologic Conjugates. 2020 , 486-499.e8	1
405	Differential localization of PD-L1 and Akt-1 involvement in radioresistant and radiosensitive cell lines of head and neck squamous cell carcinoma. 2020 , 41, 984-992	6
404	LRP11 activates Eatenin to induce PD-L1 expression in prostate cancer. 2020 , 28, 508-515	10
403	PD-1 expression affects cytokine production by ILC2 and is influenced by peroxisome proliferator-activated receptor- γ . 2020 , 8, 8-23	19
402	A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry. 2020 , 22, 842-853	7

401	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. 2020 , 21, 121-133	93
400	Foci of Programmed Cell Death-Ligand 1 (PD-L1)-positive Tumor Areas With Tumor-infiltrating Leukocytes (TILs) Evocative of a PD-1/PD-L1-related Adaptive Immune Resistance are Frequent in Merkel Cell Carcinoma. 2020 , 28, 17-22	3
399	CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors. 2020 , 30, 14-25	11
398	Biomarkers that may predict response to immunotherapy in ovarian malignancies. 2020 , 32, 84-90	5
397	PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status. 2020 , 79, 74-85	4
396	Stimuli-responsive nanoparticles for the codelivery of chemotherapeutic agents doxorubicin and siPD-L1 to enhance the antitumor effect. 2020 , 108, 1710-1724	7
395	Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma. 2020 , 122, 413-420	8
394	Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study. 2020 , 21, 134-144	47
393	Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer. 2020 , 30, 273-280	10
392	PD-1 gene rs2227981 (PD-1.5) polymorphism analysis in patients with systemic sclerosis. 2020 , 20, 100776	
391	Autonomic enteric neuropathy following nivolumab monotherapy in a patient with Lung Cancer. 2020 , 1, 100014	1
390	Oral Metformin and Polymetformin Reprogram Immunosuppressive Microenvironment and Boost Immune Checkpoint Inhibitor Therapy in Colorectal Cancer. 2020 , 3, 2000168	1
389	Isolation of DNA Aptamer Targeting PD-1 with an Antitumor Immunotherapy Effect.. 2020 , 3, 7080-7086	8
388	Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis. 2020 , 99, e21273	4
387	Increasing the expression of programmed death ligand 2 (PD-L2) but not 4-1BB ligand in colorectal cancer cells. 2020 , 47, 5689-5697	
386	Molecular Mechanism of Tumor Cell Immune Escape Mediated by CD24/Siglec-10. 2020 , 11, 1324	16
385	Management of Immune Checkpoint Inhibitor-Related Rheumatological Toxicities. 2020 , 20, 25-34	
384	Photo-Enhanced CRISPR/Cas9 System Enables Robust PD-L1 Gene Disruption in Cancer Cells and Cancer Stem-Like Cells for Efficient Cancer Immunotherapy. 2020 , 16, e2004879	8

383	Ursodeoxycholic acid and bezafibrate were useful for steroid-refractory, immune-related hepatitis: a case report. 2020 , 14, 230	2
382	High programmed death-ligand 1 expression is a poor prognostic indicator for esophageal squamous cell carcinoma and is correlated with two-field lymph node metastasis.. 2020 , 9, 2472-2481	0
381	Wee1 kinase inhibitor AZD1775 potentiates CD8+ T cell-dependent antitumour activity via dendritic cell activation following a single high dose of irradiation. 2020 , 37, 66	12
380	Correlation of PD-L1 and SOCS3 Co-expression with the Prognosis of Hepatocellular Carcinoma Patients. 2020 , 11, 5440-5448	9
379	A brief review concerning Chimeric Antigen Receptors T cell therapy. 2020 , 11, 5424-5431	1
378	Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis. 2020 , 359, 339-346	5
377	Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer. 2020 , 66, 1093-1101	17
376	Tumor Microenvironment. 2020 ,	0
375	Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study. 2020 , 10,	23
374	Tumor Microenvironment. 2020 ,	0
373	A System Biology-Based Approach for Designing Combination Therapy in Cancer Precision Medicine. 2020 , 2020, 5072697	0
372	LncRNA KCNQ10T1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1. 2020 , 20, 394	27
371	New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP. 2020 , 9, 73	7
370	Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients-Literature Review. 2020 , 12,	8
369	An Immunomodulatory Gallotannin-Rich Fraction From Enhances the Therapeutic Effect of Anti-PD-L1 in Melanoma. 2020 , 11, 584959	5
368	PD-L1 degradation pathway and immunotherapy for cancer. 2020 , 11, 955	30
367	Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features. 2020 , 83, 1130-1143	27
366	Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma. 2020 , 253, 201-213	1

365	Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer. 2020 , 12, 1758835920922033	12
364	Oncologic Emergencies: Immune-Based Cancer Therapies and Complications. 2020 , 21, 566-580	7
363	Productive screening of single aptamers with ddPCR. 2020 , 145, 4130-4137	3
362	Towards a more precise therapy in cancer: Exploring epigenetic complexity. 2020 , 57, 41-49	20
361	The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review. 2020 , 10, 533	11
360	Principles of Immunotherapy in Non-Small Cell Lung Cancer. 2020 , 30, 187-198	8
359	Tumor ablation plus co-administration of CpG and saponin adjuvants affects IL-1 production and multifunctional T cell numbers in tumor draining lymph nodes. 2020 , 8,	4
358	Regulation of sister chromatid cohesion by nuclear PD-L1. 2020 , 30, 590-601	26
357	Development of bispecific antibodies in China: overview and prospects. 2020 , 3, 126-145	13
356	Sicca syndrome following immune checkpoint inhibition. 2020 , 217, 108497	2
355	Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer. 2020 , 17, 571-585	22
354	Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study. 2020 , 10, 9705	22
353	Cautious optimism-the current role of immunotherapy in gastrointestinal cancers. 2020 , 27, S59-S68	3
352	Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease. 2020 , 13, 139	2
351	A Potential Herbal Adjuvant Combined With a Peptide-Based Vaccine Acts Against HPV-Related Tumors Through Enhancing Effector and Memory T-Cell Immune Responses. 2020 , 11, 62	10
350	CMA1 is potent prognostic marker and associates with immune infiltration in gastric cancer. 2020 , 53, 210-217	7
349	Therapeutic drugs and drug delivery systems targeting stromal cells for cancer therapy: a review. 2020 , 28, 714-726	5
348	Comprehensive review of targeted therapy for colorectal cancer. 2020 , 5, 22	312

347	Clinical Significance of Programmed Death Ligand-1 Expression in Esophageal Squamous Cell Carcinoma. 2020 , 251, 321-328	2
346	Exploiting antibody biology for the treatment of cancer. 2020 , 12, 255-267	3
345	Programmed cell death ligand-1: A dynamic immune checkpoint in cancer therapy. 2020 , 95, 552-566	7
344	Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. 2020 , 11, 159	34
343	Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells. 2020 , 18, 517-525	6
342	Photodynamic Therapy and Immune Checkpoint Blockade. 2020 , 96, 954-961	20
341	Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease. 2020 , 146, 3025-3036	6
340	Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database. 2020 , 30, 376-385	2
339	Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003. 2020 , 38, 1138-1145	19
338	Multiplexed immunohistochemistry for immune cell phenotyping, quantification and spatial distribution in situ. 2020 , 635, 51-66	8
337	Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments. 2019 , 6, 194	5
336	Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies. 2020 , 12,	25
335	PD-1/PD-L1-dependent immune response in colorectal cancer. 2020 , 235, 5461-5475	38
334	Novel cancer therapies for advanced cutaneous melanoma: The added value of radiomics in the decision making process-A systematic review. 2020 , 9, 1603-1612	10
333	Molecular Imaging for Cancer Immunotherapy: Seeing Is Believing. 2020 , 31, 404-415	19
332	Computational Staining of Pathology Images to Study the Tumor Microenvironment in Lung Cancer. 2020 , 80, 2056-2066	27
331	Biomarkers for immunotherapy response in head and neck cancer. 2020 , 84, 101977	51
330	Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects. 2020 , 6, 6-17	20

329	FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity. 2020 , 26, 3333-3344	33
328	Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry. 2020 , 26, 2268-2274	61
327	Sex differences in cancer mechanisms. 2020 , 11, 17	63
326	The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434). 2021 , 39, 152-162	4
325	Fractionated regimen-suitable immunoradiotherapy sensitizer based on ultrasmall Fe ₄ Se ₂ W ₁₈ nanoclusters enable tumor-specific radiosensitization augment and antitumor immunity boost. 2021 , 36, 101003	10
324	Metabolism and immunity in breast cancer. 2021 , 15, 178-207	5
323	The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. 2021 , 157, 103160	11
322	Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing. 2021 , 11, 694-707	10
321	Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma. 2021 , 192, 568-576	6
320	Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer. 2020 , 10, 580045	
319	Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect. 2021 , 9, 746-756	10
318	Expression of a recombinant anti-programed cell death 1 antibody in the mammary gland of transgenic mice. 2021 , 51, 183-190	1
317	Merkel cell carcinoma in Latin America: a contribution from an expanded access program for avelumab to address issues from experts' recommendations. 2021 , 70, 1031-1036	0
316	Biomarkers predicting the response to chemotherapy and the prognosis in patients with esophageal squamous cell carcinoma. 2021 , 69, 525-533	1
315	Recent advances and discoveries in the mechanisms and functions of CAR T cells. 2021 , 21, 145-161	91
314	Decreased levels of circulating cytokines VEGF, TNF- α and IL-15 indicate PD-L1 overexpression in tumours of primary breast cancer patients. 2021 , 11, 1294	1
313	Phenylboronic acid-based core-shell drug delivery platform clasping 1,3-dicarbonyl compounds by a coordinate interaction. 2021 , 9, 6851-6864	1
312	CD47/SIRP α pathway mediates cancer immune escape and immunotherapy. 2021 , 17, 3281-3287	3

311	Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma. 2021 , 13,	23
310	A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer. 2021 , 9, 4201-4210	6
309	Therapeutic Strategies Targeting Signaling Pathways in Lung Cancer. 2021 , 217-239	1
308	The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures. 2021 , 11, 567978	1
307	PD-L1 expression in peripheral T-cell lymphomas is not related to either gene amplification or rearrangements. 2021 , 62, 1648-1656	2
306	Killing efficiency affected by mutually modulated PD-1 and PD-L1 expression via NKT-hepatoma cell interactions. 2021 , 13, 113-123	0
305	Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. 2021 , 53, 141-156	25
304	Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma. 2021 , 14,	6
303	Nivolumab-caused hyperprogression of diffuse large B-cell lymphoma of the testis and spontaneous remission of type 2 diabetes mellitus in an elderly patient: a case report. 2021 , 32, 575-579	0
302	Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity. 2021 , 40, 74	2
301	PD-L1 expression in paired biopsies and surgical specimens in gastric adenocarcinoma: A digital image analysis study. 2021 , 218, 153338	2
300	Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC). 2021 , 11, 3346	4
299	PD-L1 as a Potential Target in Cancer Therapy (Review). 2021 , 10, 31-36	1
298	Immunotherapy and predictive immunologic profile: the tip of the iceberg. 2021 , 38, 51	3
297	The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy. 2021 , 895, 173867	11
296	PD-1 expression on NK cells can be related to cytokine stimulation and tissue residency.	0
295	Discovery of core gene families associated with liver metastasis in colorectal cancer and regulatory roles in tumor cell immune infiltration. 2021 , 14, 101011	3
294	Gene silencing-mediated immune checkpoint blockade for tumor therapy boosted by dendrimer-entrapped gold nanoparticles. 2021 , 64, 2045-2055	8

293	Adjuvant Therapy in Renal Cell Carcinoma: Current Status and Future Directions. 2021 , 5, 9-20	1
292	GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade. 2021 ,	21
291	Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. 2021 , 23, 39	87
290	Refractory Immune Checkpoint Inhibitor-Induced Colitis Improved by Tacrolimus: A Case Report. 2021 , 9,	2
289	Terminal Epitope-Dependent Branch Preference of Siglecs Toward -Glycans. 2021 , 8, 645999	4
288	Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review. 2021 , 21, 239	10
287	Recent progress in the treatment of cancer in children. 2021 , 71, 315-332	12
286	Recent advances in breast cancer immunotherapy: The promising impact of nanomedicines. 2021 , 271, 119110	4
285	Emerging Role of PD-1 in the Central Nervous System and Brain Diseases. 2021 , 37, 1188-1202	6
284	Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model. 2021 , 19, 102	15
283	The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy. 2021 , 28, 893-909	8
282	Z-guggulsterone induces PD-L1 upregulation partly mediated by FXR, Akt and Erk1/2 signaling pathways in non-small cell lung cancer. 2021 , 93, 107395	0
281	Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy. 2021 , 29, 3027-3041	5
280	Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. 2021 , 13,	3
279	Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T cells. 2021 , 35, 109120	13
278	Cutaneous squamous-cell carcinoma of the head-neck area refractory to chemo-radiotherapy: benefit from anti-PD-1 immunotherapy. 2021 , 7, 20200170	
277	Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development. 2021 , 11, 1083-1097	7
276	Systemic Therapy for Head and Neck Skin Cancers. 2021 , 2, 121-130	

275	LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. 2021 , 218,	8
274	From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer. 2021 , 33, e2008094	16
273	Engineering Cell Membrane-Based Nanovesicles for Melanoma Tumor Treatment. 2021 , 17, 838-845	2
272	Improving anti-PD-L1 therapy in triple negative breast cancer by polymer-enhanced immunogenic cell death and CXCR4 blockade. 2021 , 334, 248-262	6
271	Glyoxalase-1-Dependent Methylglyoxal Depletion Sustains PD-L1 Expression in Metastatic Prostate Cancer Cells: A Novel Mechanism in Cancer Immunosurveillance Escape and a Potential Novel Target to Overcome PD-L1 Blockade Resistance. 2021 , 13,	4
270	Pathogenic and therapeutic roles of cytokines in acute myeloid leukemia. 2021 , 142, 155508	1
269	Precise medicine of programmed cell death-1/programmed cell death 1 ligand 1 inhibitor immunotherapy combined radiotherapy for inoperable advanced lung cancer: A protocol for systematic review and meta-analysis. 2021 , 100, e26367	
268	Evaluation of soluble CD279 (sCD279) and CD274 (sCD274) in Iraqi patients with Acute Myeloid Leukemia (AML) with Toxoplasmosis. 2021 , 790, 012065	
267	Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. 2021 , 150, 53-62	6
266	Immune checkpoint analysis in lip cancer. 2021 , 49, 950-958	1
265	The efficacy and safety of antibodies targeting PD-1 for treatment in advanced esophageal cancer: A systematic review and meta-analysis. 2021 , 14, 101083	2
264	Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma. 2021 , 12, 672521	1
263	Trials of Immunotherapy in Triple Negative Breast Cancer. 2021 , 13, 171-185	1
262	Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. 2021 , 9,	13
261	PD-1 and PD-L2: Do they have prognostic value in lymphomas?.	
260	Stoichiometry of multi-specific immune checkpoint RNA Abs for T cell activation and tumor inhibition using ultra-stable RNA nanoparticles. 2021 , 24, 426-435	4
259	The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer. 2021 , 12, 689132	10
258	Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients. 2021 , 21, 371	1

257	The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury. 2021 , 19, 76	2
256	Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines. 2021 , 23, 13	0
255	Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer.	2
254	A secondary role for hypoxia and HIF1 in the regulation of (IFN γ -induced) PD-L1 expression in melanoma. 2021 , 1	3
253	Immune checkpoints and cancer development: Therapeutic implications and future directions. 2021 , 223, 153485	6
252	Plasmonic gold nanostars for synergistic photoimmunotherapy to treat cancer. 2021 , 10, 3295-3302	3
251	Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark. 2021 , 73, 101976	1
250	The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era. 2021 , 73, 356-376	10
249	The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients. 2021 ,	0
248	Targeting the Atf7ip-Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity. 2021 , 9, 1298-1315	1
247	Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives. 2021 , 13,	8
246	Dynamic alterations of circulating T lymphocytes and the clinical response in patients with head and neck squamous cell carcinoma treated with nivolumab. 2021 , 1	1
245	Extracellular acidity in tumor tissue upregulates programmed cell death protein 1 expression on tumor cells via proton-sensing G protein-coupled receptors. 2021 , 149, 2116-2124	1
244	Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model. 2021 , 12, 733075	0
243	Updates in the molecular pathology of non-small cell lung cancer. 2021 , 38, 54-61	3
242	A costimulatory molecule-related signature in regard to evaluation of prognosis and immune features for clear cell renal cell carcinoma. 2021 , 7, 252	4
241	Cellular and molecular regulation of the programmed death-1/programmed death ligand system and its role in multiple sclerosis and other autoimmune diseases. 2021 , 123, 102702	0
240	Role of autophagy on cancer immune escape. 2021 , 19, 91	6

239	Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer. 2021 , 11, 703802	0
238	Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research. 2021 , 14, 101153	0
237	PKC ζ regulates the expression of PDL1 through multiple pathways to modulate immune suppression of pancreatic cancer cells. 2021 , 86, 110115	0
236	Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma. 2021 , 160, 84-91	0
235	Non-Operative Options for Loco-regional Melanoma. 2021 , 48, 631-642	
234	Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy. 2021 , 909, 174404	8
233	PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy. 2021 , 226, 153605	5
232	Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer. 2021 , 227, 107870	4
231	A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine. 2021 , 522, 184-197	5
230	Endocrinopathies Associated With Immune Checkpoint Inhibitors. 2022 , 301-314	
229	Expression of cancer cell-intrinsic PD-1 associates with PD-L1 and p-S6 and predicts a good prognosis in nasopharyngeal carcinoma. 2021 , 12, 6118-6125	0
228	Targeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathways. 2021 , 6, 28	6
227	Regulatory T Cells in the Tumor Microenvironment. 2020 , 1273, 105-134	7
226	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. 2019 , 1-27	1
225	Nivolumab. 2016 , 297-317	1
224	Immunit�et cancers des voies a�o-digestives sup�erieures 2e �partie. Immunoth�erapies des cancers des VADS. 2014 , 20, 245-252	1
223	Development and Evaluation of Novel Aptamers Specific for Human PD1 Using Hybrid Systematic Evolution of Ligands by Exponential Enrichment Approach. 2020 , 49, 535-554	6
222	Non-linear tumor-immune interactions arising from spatial metabolic heterogeneity.	4

221	SHP-1 phosphatase activity counteracts increased T cell receptor affinity. 2013 , 123, 1044-56	82
220	Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. 2013 , 20, 22-31	43
219	Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme. 2019 , 19, 117	22
218	Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes. 2018 , 19, 783-789	2
217	Correlation of T Cell Immunoglobulin and ITIM Domain (TIGIT) and Programmed Death 1 (PD-1) with Clinicopathological Characteristics of Renal Cell Carcinoma May Indicate Potential Targets for Treatment. 2018 , 24, 6861-6872	10
216	Expression of B7 Homolog 1 (B7H1) Is Associated with Clinicopathologic Features in Urothelial Bladder Cancer. 2018 , 24, 7303-7308	3
215	The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells. 2015 , 10, e0134715	68
214	Identification of Novel HLA-A*24:02-Restricted Epitope Derived from a Homeobox Protein Expressed in Hematological Malignancies. 2016 , 11, e0146371	4
213	Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells. 2016 , 11, e0162925	47
212	HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis. 2017 , 12, e0172978	2
211	TIM3 Mediates T Cell Exhaustion during Mycobacterium tuberculosis Infection. 2016 , 12, e1005490	96
210	Bone Marrow Findings of Immune-Mediated Pure Red Cell Aplasia Following Anti-Programmed Cell Death Receptor-1 Therapy: A Report of Two Cases and Review of Literature. 2019 , 8, 71-78	3
209	The influence of aranoza drug formulations and «empty» liposomes on the expression of PD-L1 □ PD-L2 in human melanoma cell lines. 2017 , 16, 74-81	2
208	The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy. 2019 , 19, e277-e283	2
207	Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma. 2016 , 7, 47252-47264	65
206	Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer. 2017 , 8, 15610-15620	17
205	Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. 2017 , 8, 97671-97682	173
204	Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. 2017 , 8, 59901-59914	49

203	Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients. 2017 , 8, 101994-102005	57
202	Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area. 2015 , 6, 32484-93	36
201	PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. 2016 , 7, 19738-47	106
200	The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures. 2016 , 7, 15033-46	22
199	CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. 2016 , 7, 12024-34	112
198	Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. 2016 , 7, 30772-80	73
197	JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial. 2019 , 7, 435	9
196	Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. 2020 , 27, 2402-2448	6
195	B7-H3 Immune Checkpoint Protein in Human Cancer. 2020 , 27, 4062-4086	24
194	Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature. 2019 , 14, 100-112	11
193	Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck. 2019 , 19, 290-303	9
192	Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms. 2020 , 20, 1415-1430	1
191	Programmed Death-Ligand 1 (PD-L1) Expression Associated with a High Neutrophil/Lymphocyte Ratio in Cholangiocarcinoma. 2017 , 18, 1671-1674	16
190	Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy. 2020 , 23, 1065-1077	4
189	PCOLCE Is Potent Prognostic Biomarker and Associates With Immune Infiltration in Gastric Cancer. 2020 , 7, 544895	3
188	Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer. 2016 , 22, 4446-58	12
187	Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions. 2019 , 25, 6579-6606	13
186	[Advances of PD-1/PD-L1 signaling pathway in immune escape and treatment for ?non-small cell lung cancer]. 2014 , 17, 734-40	4

185	KCNQ1OT1 contributes to sorafenib resistance and programmed death-ligand-1-mediated immune escape via sponging miR-506 in hepatocellular carcinoma cells. 2020 , 46, 1794-1804	13
184	Significant function and research progress of biomarkers in gastric cancer. 2020 , 19, 17-29	13
183	MUC1-induced immunosuppression in colon cancer can be reversed by blocking the PD1/PDL1 signaling pathway. 2020 , 20, 317	3
182	Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis. 2015 , 7, 455-61	28
181	Immunotherapy in lung cancer. 2014 , 3, 2-14	24
180	Immunotherapy in lung cancer. 2014 , 3, 53-63	43
179	Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. 2015 , 4, 743-51	24
178	Targeted therapies in development for non-small cell lung cancer. 2013 , 12, 22	58
177	Synergistic anti-liver cancer effects of curcumin and total ginsenosides. 2020 , 12, 1091-1103	7
176	Molecular therapeutics in pancreas cancer. 2016 , 8, 366-79	16
175	Immune Escape Mechanisms in Diffuse Large B-Cell Lymphoma. 2012 , 2012, 1-6	3
174	Multifunctional Gold Nanostars for Sensitive Detection, Photothermal Treatment and Immunotherapy of Brain Tumor. 2021 , 235-255	
173	Immunotherapy. 2021 , 207-223	
172	Effect of Programmed Death-Ligand 1 in Cancer-Associated Fibroblasts on Advanced Laryngeal Squamous Cell Carcinoma. 2021 , 20, 15330338211046432	
171	The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas. 2021 , 12, 726448	2
170	Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment. 2021 , 22,	1
169	THE INTESTINAL COMMENSAL, , MODULATES HOST RESPONSES TO VIRAL INFECTION AND THERAPY: LESSONS FOR EXPLORATION DURING INFECTION. 2021 , IAI0032121	4
168	Metabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice. 2021 , 13, eaba6006	3

- 167 Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction. **2021**, 6, 146-159
- 166 Palmitoylation of PD-L1 Regulates Its Membrane Orientation and Immune Evasion. ○
- 165 Dendritic Cells and Cancer: Development, Dysfunction and Therapeutic Targets. **2013**, 431-455
- 164 T Cell Co-regulatory Signals and Their Role in Cancer Therapy. **2014**, 323-341
- 163 Engineering DNA Vaccines for Cancer Therapy. **2014**, 449-471
- 162 Therapeutic Antibodies and Immunologic Conjugates. **2014**, 508-518.e7 ○
- 161 Overcoming Cancer Tolerance with Immune Checkpoint Blockade. **2015**, 87-129
- 160 Development and Incorporation of Biomarkers in RCC Therapeutics. **2015**, 527-539
- 159 Immune Checkpoint Inhibitors (Anti-CTLA4, Anti-PD-1) in RCC. **2015**, 469-481
- 158 Mechanisms and Modulation of Tumor Microenvironment-Induced Immune Resistance. **2015**, 143-158
- 157 T Cell Modulation: Anti-PD-1 Antibodies for the Treatment of Cancer. **2015**, 231-244
- 156 Immunopharmacologic Approaches to Treat Cancer. **2016**, 397-425
- 155 Pembrolizumab. **2016**, 319-332
- 154 Translational Research and Immunotherapy in Lung Cancer. **2016**, 255-296
- 153 Monoclonal Antibodies in Pediatric Acute Lymphoblastic Leukemia. **2017**, 201-237
- 152 Immunotherapy for Renal Cell Cancer (RCC). **2017**, 295-317
- 151 Immune Checkpoint Inhibitors in Melanoma Define a New Era in Immunotherapy Aiming for Cure. **2017**, 427-436
- 150 A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy. **2017**, 5, 1-5

149 Virotherapies in Pancreatic Cancer. **2018**, 309-322

148 REVIEW OF APPROACHES TO IMMUNOTHERAPY IN ONCOLOGY. **2017**, 4, 51-65

1

147 Anti-programmed death ligand 1 (PD-L1) inhibitors in metastatic gastric cancer. **2017**, 1, 152-158

146 Lipopolysaccharide Potentiates PD-1 Targeted Therapies During Chronic Viral Infection.

145 The Effect of Pembrolizumab in Absence of Programmed Death 1 Receptor. **2018**, 10, e2896

1

144 Biological Events and Barriers to Effective Delivery of Cancer Therapeutics. **2019**, 13-31

143 Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. **2019**, 1-24

142 The prognostic value of tumor PD-L1 status in patients with metastatic prostate cancer. **2019**, 15, 57-65

8

141 Computational staining of pathology images to study tumor microenvironment in lung cancer.

140 Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. **2020**, 1141-1164

139 Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors. **2020**, 3, 121-127

138 Overcoming Cancer Tolerance with Immune Checkpoint Blockade. **2021**, 85-128

137 Lentinan, a Shiitake Mushroom β -Glucan, Downregulates the Enhanced PD-L1 Expression Induced by Platinum Compounds in Gastric Cancer Cells -. 9, 1-10

1

136 Lipoproteins and the Tumor Microenvironment. **2020**, 1272, 93-116

1

135 Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. **2020**, 1215-1241

134 Key Signaling Pathways Engaged in Cancer Management: Current Update. **2020**, 16, 36-48

0

133 Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy. **2021**, 64, 15716-15726

4

132 The Role of TGF- β in Bone Metastases. **2021**, 11,

4

131 Immunotherapy. 247-260

130	Beyond Promoter: The Role of Macrophage in Invasion and Progression of Renal Cell Carcinoma. 2020 , 15, 588-596	1
129	The role of IL-27 in the induction of anti-tumor cytotoxic T lymphocyte response. 2013 , 5, 470-80	9
128	Prognostic value of immune cell infiltration, tertiary lymphoid structures and PD-L1 expression in Merkel cell carcinomas. 2014 , 7, 7610-21	35
127	Novel Therapies in Development for Metastatic Colorectal Cancer. 2014 , 7, S2-7	2
126	How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know. 2016 , 7, 498-509	6
125	Immune reaction by cytoreductive prostatectomy. 2019 , 7, 64-79	2
124	The prognostic significance of pd1 and foxp3 expressions in tumor cells and the tumor microenvironment of ovarian epithelial tumors. 2018 , 11, 3884-3890	
123	Abnormal Ecatenin expression and reduced tumor-infiltrating T cells are related to poor progression in non-small cell lung cancer. 2017 , 10, 11572-11579	1
122	Ultrathin metal-organic layer-mediated radiotherapy-radiodynamic therapy enhances immunotherapy of metastatic cancers. 2019 , 1, 1331-1353	16
121	Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer. 2020 , 9, 1028-1041	2
120	Biliary tract cancers: moving from the present standards of care towards the use of immune checkpoint inhibitors. 2021 , 13, 8598-8610	
119	Immunopharmacogenomics: clinical applications, challenges, and future prospects. 2022 , 255-276	
118	A Novel Strategy Conjugating PD-L1 Polypeptide With Doxorubicin Alleviates Chemotherapeutic Resistance and Enhances Immune Response in Colon Cancer. 2021 , 11, 737323	0
117	Fractional Laser Treatment Boosts Systemic Anti-Tumor Immunity in Combination with OX40 Agonist and PD-1 Blockade.	
116	Clinical Observation of the Treatment of Triple Negative Breast Cancer with the Combination of the Tislelizumab and the Chemotherapy. 2021 , 11, 5717-5722	
115	Frequent Quantitation of Circulating Tumor Cells Predictive of Real-Time Therapy Response.	
114	Tertiary lymphoid structures in cancer.. 2022 , 375, eabf9419	19

113	Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.. 2022 , 10,	2
112	The anti-tumor effects of CT-26 derived exosomes enriched by MicroRNA-34a on murine model of colorectal cancer.. 2021 , 290, 120234	1
111	PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?. 2021 , 103, 108484	0
110	Breast Cancer Immunotherapy: From Biology to Current Clinical Applications. 113-124	1
109	Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer. 2020 , 9, 1028-1041	3
108	PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma.. 2022 , 156, 453	
107	Immune Profile by Multiplexed Immunohistochemistry Associated with Recurrence after Chemoradiation in Rectal Cancer.. 2022 ,	0
106	Exosome application in tumorigenesis: diagnosis and treatment of melanoma.. 2022 , 39, 19	2
105	The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors.. 2021 , 12, 802049	0
104	CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunecheckpoint blockade.. 2022 , 27, 998-1009	1
103	Allogeneic gene-edited HIV-specific CAR-T cells secreting PD-1 blocking scFv enhance anti-HIV activity in vitro.	0
102	Quenching Epigenetic Drug Resistance Using Anti-hypoxic Microparticles in Glioblastoma Patient-derived Chips.. 2021 , e2102226	2
101	Immunotherapy for Esophageal Cancer: State-of-the Art in 2021.. 2022 , 14,	1
100	Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function.. 2022 , 219,	2
99	ATRA promotes PD-L1 expression to control gastric cancer immune surveillance.. 2022 , 174822	
98	The Challenge to the Pathologist of PD-L1 Expression in Tumor Cells of Non-Small-Cell Lung Cancer-An Overview.. 2021 , 28, 5227-5239	0
97	METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N-methyladenosine modification of PD-L1 mRNA in breast cancer.. 2022 , 21, 60	3
96	Uncovering Pharmacological Opportunities for Cancer Stem Cells-A Systems Biology View.. 2022 , 10, 752326	1

95	The immune microenvironment in gastric adenocarcinoma.. 2022,	5
94	In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer.	
93	Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.. 2022, 13, 827921	4
92	Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors.. 2022, 12,	0
91	Clinical tissue biomarker digital image analysis: A review of current applications. 2022, 28, 300633	2
90	Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy.. 2022, 16, 107-119	2
89	Differential Expression of PD-L1 during Cell Cycle Progression of Head and Neck Squamous Cell Carcinoma. 2021, 22,	0
88	Current Advancements of Plant-Derived Agents for Triple-Negative Breast Cancer Therapy through Deregulating Cancer Cell Functions and Reprogramming Tumor Microenvironment.. 2021, 22,	0
87	E-cadherin on epithelial-mesenchymal transition in thyroid cancer.. 2021, 21, 695	2
86	Disruption of Her2-Induced PD-L1 Inhibits Tumor Cell Immune Evasion in Patient-Derived Gastric Cancer Organoids.. 2021, 13,	1
85	Emerging immunological strategies: recent advances and future directions. 2021, 15, 805	0
84	Combination Biomarker of Immune Checkpoints Predict Prognosis of Urothelial Carcinoma.. 2021, 10,	0
83	NDRG2 Expression in Breast Cancer Cells Downregulates PD-L1 Expression and Restores T Cell Proliferation in Tumor-Coculture. 2021, 13,	2
82	Data_Sheet_1.PDF. 2019,	
81	Data_Sheet_2.xlsx. 2019,	
80	Image_1.TIFF. 2020,	
79	Image_10.TIFF. 2020,	
78	Image_2.TIFF. 2020,	

77 Image_3.TIFF. 2020,

76 Image_4.TIFF. 2020,

75 Image_5.TIFF. 2020,

74 Image_6.TIFF. 2020,

73 Image_7.TIFF. 2020,

72 Image_8.TIFF. 2020,

71 Image_9.TIFF. 2020,

70 Image_1.jpeg. 2018,

69 Image_3.jpeg. 2018,

68 Image_4.jpeg. 2018,

67 Image_5.jpeg. 2018,

66 Image_6.jpeg. 2018,

65 Presentation_1.pdf. 2020,

64 image_1.PDF. 2018,

63 Image1.PDF. 2018,

62 Image2.PDF. 2018,

61 Image3.PDF. 2018,

60 Image4.PDF. 2018,

59	Presentation1.pdf. 2018,	
58	Table1.PDF. 2018,	
57	Table2.PDF. 2018,	
56	Table3.PDF. 2018,	
55	Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy.. 2022,	9
54	Sirolimus therapy restores the PD-1+ICOS+Tfh:CD45RA-Foxp3 activated Tfr cell balance in primary Sjögren's syndrome.. 2022, 147, 90-100	0
53	Polyaniline-Based Glyco-Condensation on Au Nanoparticles Enhances Immunotherapy in Lung Cancer.. 2022,	0
52	The importance of N6-methyladenosine modification in tumor immunity and immunotherapy.. 2022, 11, 30	0
51	Human microbiota: a crucial gatekeeper in lung cancer initiation, progression, and treatment. 2022, 100055	
50	Understanding the tumor microenvironment in head and neck squamous cell carcinoma. 2022, 11,	0
49	The Role of Surgery in Management of Gastric Cancer. 2022, 421-430	
48	Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. 2022, 7,	8
47	Immunorthodontics: Role of HIF-1 α in the Regulation of (Peptidoglycan-Induced) PD-L1 Expression in Cementoblasts under Compressive Force. 2022, 23, 6977	0
46	Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. 2022, 12, 1073	3
45	CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models. 2022, 14, 3361	1
44	Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer. 2022, 1-20	
43	A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma. 13,	0
42	HOXA11-AS1 Promotes PD-L1-Mediated Immune Escape and Metastasis of Hypopharyngeal Carcinoma by Facilitating PTBP1 and FOSL1 Association. 2022, 14, 3694	

41	Immunotherapeutic targets in non-small cell lung cancer.	1
40	Non-apoptotic activity of the mitochondrial protein SMAC/Diablo in lung cancer: Novel target to disrupt survival, inflammation, and immunosuppression. 12,	0
39	Successes and failures of immunotherapy for gastric cancer. 2022 , 27, 103343	0
38	Rational development of molecularly imprinted nanoparticles for blocking PD-1/PD-L1 axis. 2022 , 13, 10897-10903	2
37	PD-L1, a Potential Immunomodulator Linking Immunology and Orthodontically Induced Inflammatory Root Resorption (OIIRR): Friend or Foe?. 2022 , 23, 11405	1
36	Characterizing the immune checkpoint marker profiles of cutaneous squamous cell carcinomas in patients with hidradenitis suppurativa.	0
35	A case of pembrolizumab-induced hypopituitarism subsequent to hypothyroidism. 2022 , 48, 295-300	0
34	Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo. 2022 , 21, 153303382211332	0
33	PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application. 2022 , 114, 352-364	1
32	Bridging the Scientific Gaps to Identify Effective Treatments in Adrenocortical Cancer. 2022 , 14, 5245	0
31	Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers. 2022 , 14, 4985	2
30	Tumor immune microenvironment in therapy-naïve esophageal adenocarcinoma could predict the nodal status.	0
29	A novel non-viral PDCD1 site-integrated CAR design: killing 2 birds with 1 stone. 2022 , 4, 211-213	0
28	Distinct CD4+ T cell signature in ANA-positive young adult patients. 13,	1
27	Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. OF1-OF13	0
26	Tumor Microenvironment-Activated Hydrogel Platform with Programmed Release Property Evokes a Cascade-Amplified Immune Response against Tumor Growth, Metastasis and Recurrence. 2107061	0
25	Amplified cancer immunotherapy of PD-L1 blockade by sequential tumor microenvironment reshaping and DC maturation. 2023 , 453, 139795	0
24	Understanding the regulation of Don't Eat Me signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy.	0

- 23 Expression of plant-produced anti-PD-L1 antibody with anoikis sensitizing activity in human lung cancer cells via., suppression on epithelial-mesenchymal transition. **2022**, 17, e0274737 ○
- 22 A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance. OF1-OF11 ○
- 21 Immune checkpoint inhibitors as neoadjuvant therapy in early triple-negative breast cancer: A systematic review and meta-analysis. **2022**, 18, 1754 ○
- 20 Screening and identification of an anti-PD-1 nanobody with antitumor activity. ○
- 19 Regulatory T lymphocytes as a therapy for ischemic stroke. ○
- 18 Melatonin Inhibits EMT in Bladder Cancer by Targeting Autophagy. **2022**, 27, 8649 ○
- 17 The AdipocyteMacrophage Relationship in Cancer: A Potential Target for Antioxidant Therapy. **2023**, 12, 126 ○
- 16 Allogeneic gene-edited HIV-specific CAR-T cells secreting PD-1 blocking scFv enhance specific cytotoxic activity against HIV Env+ cells in vivo. **2023**, ○
- 15 Tertiary lymphoid structures in breast ductal carcinoma in situ correlate with adverse pathologic parameters. 1
- 14 Laboratory predictors to intravesical BCG therapy response in patients with non-muscle invasive bladder cancer. **2023**, 10, 155-164 ○
- 13 Treatment of Parathyroid Cancer: Current Status and Near-Term Prospects. **2022**, 77, 362-370 ○
- 12 Perspektiven der medikamentösen Tumorthherapie. **2022**, 335-357 ○
- 11 Syngeneic N1-S1 Orthotopic Hepatocellular Carcinoma in Sprague Dawley Rat for the Development of Interventional Oncology-Based Immunotherapy: Survival Assay and Tumor Immune Microenvironment. **2023**, 15, 913 ○
- 10 KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?. ○
- 9 Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC. **2023**, 11, 508 ○
- 8 Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer. **2023**, 23, 227-233 ○
- 7 Roles of Tumor Immune Microenvironment in Non-small Cell Lung Cancer. **2023**, ○
- 6 A clinical case of immune-mediated pneumonitis after nivolumab in a patient with Burkitt lymphoma. **2023**, 18, 121-125 ○

- 5 The Effect of Different Concentrations of Anti-PD-1 and Anti-PD-L1 Antibodies on the Activity of Immune System Cells in Patients With Non-small Cell Lung Cancer. ○
- 4 Sicca symptoms and sialoadenitis as immune-related adverse events of nivolumab treatment in renal malignancy. **2023**, 13, 21-23 ○
- 3 Application of single cell multiomics points to changes in chromatin accessibility near calcitonin receptor like receptor and a possible role for adrenomedullin in the post-shock lung. 10, ○
- 2 A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer. **2023**, 40, ○
- 1 Fatty Acid Binding Protein 5 (FABP5) Promotes Aggressiveness of Gastric Cancer Through Modulation of Tumor Immunity. **2023**, 23, 340 ○